E-QURE Corp. Issues 2014 - 2015 Update to Shareholders
PR Newswire - Tue May 05, 8:00AM CDT
E-QURE (Electric Quick Ulcer Remedy) Corp. (OTCQB: EQUR); ("E-QURE" or the "Company"
Our Thoughts And Forecasts On E-Qure For 2015
Anita Dushyanth - at Seeking Alpha - Tue Apr 21, 12:38PM CDT
E-QURE has established a Scientific Advisory Board appointing Dr. Ben-Zion Weiner and Prof. Avi Ohry
ACCESSWIRE - Sun Apr 12, 11:58AM CDT
The Wound Healing Medical Device Company Nominated Two Prominent, Well Experiences Scientists, To Guide The Company In Its Coming Clinical Trial And Industry Recognition
TEVA: 60.23 (-0.99)
UniQure Deal Confirms Red-Hot Interest In Advanced Therapies
EP Vantage - at Seeking Alpha - Tue Apr 07, 3:42PM CDT
If there is any sign that pharma is beating the bushes to flush out promising advanced therapies, it is that Bristol-Myers Squibb (NYSE: BMY ) has shelled out $50m to license a preclinical gene therapy project that UniQure (NASDAQ: QURE ) ...
BLUE: 154.42 (-2.98), CLDN: 2.18 (-0.17), BMY: 67.64 (+0.19)